J Schneider1, M Henningsen1, P Pisarski2, G Walz1, B Jänigen2. 1. Department of Medicine IV, Medical Center, Faculty of Medicine, University of Freiburg, Germany. 2. Department of General and Digestive Surgery, Section of Transplant Surgery, Medical Center, Faculty of Medicine, University of Freiburg, Germany.
Abstract
BACKGROUND: Leukopenia is a common problem after kidney transplantation. The therapeutic approach typically includes a reduction of the immunosuppressive therapy, which is associated with an increased risk of rejection and allograft loss. Granulocyte colony-stimulating factor (G-CSF) is used as a therapeutic option to raise the leukocyte blood count; however, the effect on acute rejections is controversial. OBJECTIVE: The goal of this study is to examine the incidence of acute rejections following G-CSF therapy. METHODS: We retrospectively evaluated patients with leukopenia following kidney transplantation and GCSF therapy between January 2007 and December 2017 at our center compared to controls with matched minimal leucocyte blood count in a matched pair analysis. RESULTS: We identified 12 patients, who received G-CSF therapy with a cumulative dose of 10.74 µg/kg body weight over a time frame of 4.3 days. G-CSF therapy resulted in a significantly shorter time period with leucocytes <3,000/µL (9.5 vs. 16.6 days), but also trended towards an increased risk of rejection within the next 30 days with three patients in the G-CSF group and no patient in the control group (p=0.06) developing an acute biopsy-proven rejection. Infection and mortality rate in the subsequent year were not different between groups. CONCLUSION: G-CSF therapy decreases the duration of leukopenia post-kidney transplantation, but may also increase the risk of an acute rejection.
BACKGROUND: Leukopenia is a common problem after kidney transplantation. The therapeutic approach typically includes a reduction of the immunosuppressive therapy, which is associated with an increased risk of rejection and allograft loss. Granulocyte colony-stimulating factor (G-CSF) is used as a therapeutic option to raise the leukocyte blood count; however, the effect on acute rejections is controversial. OBJECTIVE: The goal of this study is to examine the incidence of acute rejections following G-CSF therapy. METHODS: We retrospectively evaluated patients with leukopenia following kidney transplantation and GCSF therapy between January 2007 and December 2017 at our center compared to controls with matched minimal leucocyte blood count in a matched pair analysis. RESULTS: We identified 12 patients, who received G-CSF therapy with a cumulative dose of 10.74 µg/kg body weight over a time frame of 4.3 days. G-CSF therapy resulted in a significantly shorter time period with leucocytes <3,000/µL (9.5 vs. 16.6 days), but also trended towards an increased risk of rejection within the next 30 days with three patients in the G-CSF group and no patient in the control group (p=0.06) developing an acute biopsy-proven rejection. Infection and mortality rate in the subsequent year were not different between groups. CONCLUSION: G-CSF therapy decreases the duration of leukopenia post-kidney transplantation, but may also increase the risk of an acute rejection.
Authors: Stephanie Hamel; Vicky Kuo; Deirdre Sawinski; David Johnson; Roy D Bloom; Melissa Bleicher; Simin Goral; Mary Ann Lim; Jennifer Trofe-Clark Journal: Clin Transplant Date: 2019-04-11 Impact factor: 2.863
Authors: A Wasler; F Iberer; T Auer; B Petutschnigg; H Müller; J Pfeifer; T Deutsch; K H Tscheliessnigg Journal: Transplant Proc Date: 1995-10 Impact factor: 1.066
Authors: N Turgeon; G K Hovingh; J A Fishman; N Basgoz; N E Tolkoff-Rubin; M Doran; A B Cosimi; R H Rubin Journal: Transpl Infect Dis Date: 2000-03 Impact factor: 2.228
Authors: L Zafrani; L Truffaut; H Kreis; D Etienne; C Rafat; S Lechaton; D Anglicheau; J Zuber; M Ciroldi; E Thervet; R Snanoudj; M F Mamzer; F Martinez; M O Timsit; L Bergougnoux; C Legendre Journal: Am J Transplant Date: 2009-06-16 Impact factor: 8.086
Authors: Laneshia Karee Tague; Davide Scozzi; Michael Wallendorf; Brian F Gage; Alexander S Krupnick; Daniel Kreisel; Derek Byers; Ramsey R Hachem; Andrew E Gelman Journal: Am J Transplant Date: 2019-09-26 Impact factor: 8.086